Stakeholders brace for bumps in rare pediatric disease PRV reauthorization

A voucher program designed to stimulate drug development for rare pediatric diseases will sunset later this year if lawmakers don’t reauthorize it — and rare disease advocates and experts are bracing for bumps in the road to renewal.

The Rare Pediatric Disease Priority Review Voucher Program allows the FDA to…
Click here to view original post

Click Here to Publish/Feature Your Company or Product News with Biotech Networks